SK9892003A3 - An improved process for preparing pure ondansetron hydrochloride dihydrate - Google Patents

An improved process for preparing pure ondansetron hydrochloride dihydrate Download PDF

Info

Publication number
SK9892003A3
SK9892003A3 SK989-2003A SK9892003A SK9892003A3 SK 9892003 A3 SK9892003 A3 SK 9892003A3 SK 9892003 A SK9892003 A SK 9892003A SK 9892003 A3 SK9892003 A3 SK 9892003A3
Authority
SK
Slovakia
Prior art keywords
ondansetron
solution
precipitate
methylcarbazolone
hydrochloride
Prior art date
Application number
SK989-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Ramy Lidor Hadas
Eliezer Bachar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SK9892003A3 publication Critical patent/SK9892003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
SK989-2003A 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate SK9892003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26105201P 2001-01-11 2001-01-11
PCT/US2002/000853 WO2002055492A2 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Publications (1)

Publication Number Publication Date
SK9892003A3 true SK9892003A3 (en) 2004-05-04

Family

ID=22991757

Family Applications (1)

Application Number Title Priority Date Filing Date
SK989-2003A SK9892003A3 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Country Status (21)

Country Link
EP (1) EP1355881A4 (ko)
JP (1) JP2004526692A (ko)
KR (3) KR20060113792A (ko)
CN (2) CN1496350A (ko)
AU (1) AU2002236753B2 (ko)
CA (1) CA2433720A1 (ko)
CZ (1) CZ20032090A3 (ko)
DE (1) DE02703115T1 (ko)
ES (1) ES2219201T1 (ko)
HR (1) HRP20030631A2 (ko)
HU (1) HUP0400767A2 (ko)
IL (1) IL156835A0 (ko)
IS (1) IS6869A (ko)
MX (1) MXPA03006215A (ko)
NO (1) NO20033147L (ko)
PL (1) PL368837A1 (ko)
SK (1) SK9892003A3 (ko)
TR (1) TR200401460T3 (ko)
WO (1) WO2002055492A2 (ko)
YU (1) YU56103A (ko)
ZA (1) ZA200305338B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098345B2 (en) 2002-04-29 2006-08-29 TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
US7696356B2 (en) 2004-08-17 2010-04-13 Taro Pharmaceutical Industries Limited Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
EP1828141A4 (en) * 2004-10-26 2009-04-01 Ipca Lab Ltd STAINING METHOD FOR PREPARING THE ANTIEMETIC 1,2,3,9-TETRAHYDRO-9-METHYL-3 - [(2-METHYL) -1H-IMIDAZOLE-1-YL) METHYL] -4H-CARBAZOLE-4-ON

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
EP1339707A2 (en) * 2000-10-30 2003-09-03 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Also Published As

Publication number Publication date
CN101045704A (zh) 2007-10-03
NO20033147D0 (no) 2003-07-09
WO2002055492A2 (en) 2002-07-18
CZ20032090A3 (cs) 2004-08-18
PL368837A1 (en) 2005-04-04
EP1355881A4 (en) 2004-03-31
NO20033147L (no) 2003-09-02
MXPA03006215A (es) 2005-02-17
HRP20030631A2 (en) 2005-06-30
AU2002236753B2 (en) 2007-06-28
EP1355881A2 (en) 2003-10-29
YU56103A (sh) 2006-05-25
IL156835A0 (en) 2004-02-08
IS6869A (is) 2003-07-08
KR20030068583A (ko) 2003-08-21
KR20070054749A (ko) 2007-05-29
CN1496350A (zh) 2004-05-12
JP2004526692A (ja) 2004-09-02
HUP0400767A2 (hu) 2004-07-28
TR200401460T3 (ko) 2004-08-23
ZA200305338B (en) 2004-07-12
CA2433720A1 (en) 2002-07-18
WO2002055492A3 (en) 2003-02-13
KR20060113792A (ko) 2006-11-02
ES2219201T1 (es) 2004-12-01
DE02703115T1 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
CN101547892B (zh) 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
CN111630049B (zh) 用于制备2-(5-甲氧基异色满-1-基)-4,5-二氢-1h-咪唑及其硫酸氢盐的方法
CA2942301A1 (en) Clomiphene synthesis using a single solvent
EP3015453A1 (en) Process for the preparation of Clomiphene
SK9892003A3 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
TWI756418B (zh) 2-([1,2,3]三唑-2-基)-苯甲酸衍生物之製備
RU2437878C2 (ru) Способы получения гетероциклических соединений
JPH02218682A (ja) エルゴリン誘導体
CN112759546B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物及其制备方法和药物用途
AU2002236753A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
EA011748B1 (ru) Способ получения рисперидона
US20020115707A1 (en) Process for preparing pure ondansetron hydrochloride dihydrate
JP6808088B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストとしてのフルオロピペリジン化合物
EP3015454A1 (en) Stable solid form of trans-Clomiphene citrate
CZ306203B6 (cs) Způsob syntézy lurasidonu
KR101694262B1 (ko) 실로도신의 결정형의 제조방법
EP2072510A1 (en) Crystalline form of azelastine
KR102718536B1 (ko) 2-(5-메톡시이소크로만-1-일)-4,5-디하이드로-1h-이미다졸 및 이의 하이드로젠설페이트 염의 제조방법
KR101733084B1 (ko) 실로도신의 결정형의 제조방법
EP2691387B1 (en) Process for the preparation of anhydrous aripiprazole crystal form ii
WO2008149152A1 (en) Novel process
AU2022360035A1 (en) Synthesis of mavorixafor and intermediates thereof
WO2014049609A2 (en) Novel salts of vilazodone
JP2024538727A (ja) マボリキサフォルの合成およびその中間体
JPH1067795A (ja) エリスロマイシン誘導体の製造法

Legal Events

Date Code Title Description
FC9A Refused patent application